Grade III-A · MOE Key Laboratory
Established
1976
Beds
1,000+
Annual Volume
800,000+
Beijing
National leader in GI oncology and lymphoma; a model institution for MDT-based cancer care.
Peking University Cancer Hospital (Beijing Cancer Hospital), founded in 1976 on a ~33,216 sqm campus, is a grade-A tertiary cancer hospital integrating care, teaching, research and prevention, and leads the nation in gastrointestinal oncology (gastric and colorectal cancers).
The hospital has distinctive strengths in perioperative gastric cancer treatment, precision therapy for advanced GI tumors, melanoma and genitourinary oncology, with multiple research findings incorporated into international guidelines.
01National leader in GI oncology
Professor Ji Jiafu’s gastric surgery team led practice-changing studies such as RESOLVE; Professor Shen Lin’s GI medical-oncology team leads the nation in advanced precision therapy and clinical research.
02Distinctive melanoma and kidney cancer programs
Professor Guo Jun’s team established diagnostic and treatment standards for acral and mucosal melanoma — subtypes rare in the West — providing key evidence for international guidelines.
03New-drug clinical research platform
Its phase I unit runs numerous globally synchronized early-phase studies, offering advanced patients access to frontier therapies.
Prof. Shen Lin’s team led multiple international phase III studies that changed gastric and esophageal cancer practice in China, advancing domestic PD-1 inhibitors into first-line standard care.
Prof. Zhu Jun’s team built a full-course lymphoma management system spanning autologous stem-cell transplant to CAR-T therapy, with multiple cell-therapy results published internationally.